A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Summary

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Timeline

Start

2026-02-24

Primary completion

2027-07-30

Completion

2027-07-30

Drugs

Indications